Results 81 to 90 of about 142,623 (303)
Atractylodes lactone compounds inhibit platelet activation
Platelets, 2017 Platelets play a crucial role in the development and progression of atherosclerosis-thrombosis and, therefore, antiplatelet drugs are widely used in the treatment of coronary artery disease. Moreover, advances in understanding the biological functions of
Yizhu Chen +6 more
doaj +1 more source
Newer agents in antiplatelet therapy: a review
, 2012 Jennifer Yeung, Michael HolinstatCardeza Foundation for Hematologic Research, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USAAbstract: Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in ...
Yeung J, Holinstat M
core
British Journal of Clinical Pharmacology, EarlyView.Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed +7 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT).
John K. Bartoli‐Abdou +10 more
wiley +1 more source
, 2018 Antiplatelet agents are commonly used in vascular medicine and cardiology, but also in the pharmacologic management of patients with ischemic stroke. Aspirin alone remains the mainstay of therapy for secondary stroke prevention.
Sarah L. Clark, Eelco F. M. Wijdicks
core +1 more source
Republished: Antiplatelet therapy for secondary prevention of coronary artery disease [PDF]
, 2015 The choice and duration of antiplatelet therapy for secondary prevention of coronary artery disease (CAD) is determined by the clinical context and treatment strategy.
Windecker, Stephan, Pilgrim, Thomas
core +1 more source
Drug‐coated balloons: From conventional designs to next‐generation innovations in vascular therapy
BMEMat, EarlyView.This review traces the evolution of drug‐coated balloons (DCBs) from conventional designs to next‐generation platforms. We highlight innovations in balloon engineering, coating technologies, and therapeutic agents that enhance localized drug delivery while addressing challenges in efficiency, safety, and biocompatibility for vascular and emerging non ...
Lu Zhang +5 more
wiley +1 more source
Cognitive Impairment, Depression and Cerebral Microbleeds in Immune Thrombocytopenia (ITP)
American Journal of Hematology, EarlyView.
Camelia Vladescu +10 more
wiley +1 more source
Harnessing blood clot as a native scaffold for orchestrating tissue repairs and regeneration
BMEMat, EarlyView.The blood clot, owing to its dynamic composition and unique microenvironment, holds significant yet underappreciated potential for tissue engineering. This review systematically summarizes the pathophysiology of clot formation, the key regulatory factors shaping its microenvironment, and its applications in both pre‐clinical and clinical settings ...
Gao‐peng Dang +13 more
wiley +1 more source
Antiplatelet therapy for secondary prevention of coronary artery disease. [PDF]
, 2014 The choice and duration of antiplatelet therapy for secondary prevention of coronary artery disease (CAD) is determined by the clinical context and treatment strategy.
Windecker, Stephan, Pilgrim, Thomas
core +1 more source